Zura Bio Ltd (ZURA)
$5.79-$0.06 (-0.99%) Today
Jennifer Jarrett
Ajay NirulaZura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 7 | 357,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
29 Form 4 filings on record, the earliest from Nov 27, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jennifer Jarrett | Grant or award | Share Option (Right to Buy) | 51,000 | $0.00 | - | |
| Parvinder Thiara | Grant or award | Share Option (Right to Buy) | 51,000 | $0.00 | - | |
| Steven J. Schoch | Grant or award | Share Option (Right to Buy) | 51,000 | $0.00 | - | |
| Ajay Nirula | Grant or award | Share Option (Right to Buy) | 51,000 | $0.00 | - | |
| Amit Munshi | Grant or award | Share Option (Right to Buy) | 51,000 | $0.00 | - | |
| Mark Eisner | Grant or award | Share Option (Right to Buy) | 51,000 | $0.00 | - | |
| Daniel J. Becker | Grant or award | Share Option (Right to Buy) | 51,000 | $0.00 | - | |
| Gary Whale - Officer | Grant or award | Employee Share Option (Right to Buy) | 263,000 | $0.00 | - | |
| Kiran Nistala - Officer | Grant or award | Employee Share Option (Right to Buy) | 340,900 | $0.00 | - | |
| Eric J. Hyllengren - Officer | Grant or award | Employee Share Option (Right to Buy) | 340,900 | $0.00 | - | |
| Kim Davis - Officer | Grant or award | Employee Share Option (Right to Buy) | 425,700 | $0.00 | - | |
| Sandeep Chidambar Kulkarni - Officer | Grant or award | Employee Share Option (Right to Buy) | 894,000 | $0.00 | - | |
| Ajay Nirula | Grant or award | Share Option (Right to Buy) | 37,812 | $0.00 | - | |
| AI Biotechnology LLC | Open-market purchase | Class A Ordinary Shares | 2,000,000 | $6.25 | $12.50M | |
| Mark Eisner | Grant or award | Share Option (Right to Buy) | 37,812 | $0.00 | - | |
| Parvinder Thiara | Grant or award | Share Option (Right to Buy) | 38,823 | $0.00 | - | |
| Sandeep Chidambar Kulkarni - Officer | Grant or award | Employee Share Option (Right to Buy) | 2,934,107 | $0.00 | - | |
| Eric J. Hyllengren - Officer | Grant or award | Employee Share Option (Right to Buy) | 672,000 | $0.00 | - | |
| Kim Davis - Officer | Grant or award | Class A Ordinary Shares | 500 | $0.00 | - | |
| Kim Davis - Officer | Grant or award | Class A Ordinary Shares | 1,000 | $0.00 | - | |
| Sandeep Chidambar Kulkarni | Grant or award | Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| van Amstel Arnout Ploos | Grant or award | Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| Robert Lisicki - Officer | Grant or award | Employee Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| Steven J. Schoch | Grant or award | Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| Amit Munshi | Grant or award | Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| Neil Murray Hamilton Graham | Grant or award | Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| Parvinder Thiara | Grant or award | Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| Someit Sidhu | Grant or award | Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| Jennifer Jarrett | Grant or award | Share Option (Right to Buy) | 117,000 | $0.00 | - | |
| Parvinder Thiara | Open-market sale | Class A Ordinary Shares | 1,001,633 | $2.73 | $2.73M |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| SOMEIT SIDHU | Director | 50,000 | $288K | View on EDGAR | |
| SOMEIT SIDHU | Director | 27,000 | $151K | View on EDGAR | |
| SOMEIT SIDHU | Director | 40,000 | $221K | View on EDGAR |
Zura Bio Ltd (ZURA) had 7 insider filings in the last 90 days, with the most recent on 2026-06-22. The full record for ZURA runs to 29 Form 4 filings, the earliest from 2024-11-27. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ZURA were filed in the last 90 days. 1 purchase is on record for this company.
No insider sales of ZURA were filed in the last 90 days. 1 sale is on record for this company.
This page tracks ZURA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ZURA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
